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Abstract 
 Approximately 1 in 8 women in the United States will be diagnosed with breast cancer.1 
Among these women, 25-30% will have breast cancer where the HER2 gene is overexpressed 
and human epidermal growth factor receptor 2 (HER2) is overexpressed, which increases the 
aggressiveness of the cancer.2 The aggressiveness of HER2-positive breast cancer results in 
decreased long-term survival. For this reason, new HER-2 targeted therapies need to be 
developed to increase remission and survival of HER2-postive breast cancer patients. A notable 
success in this field has been the use of Genentech’s anti-HER2 antibody (Herceptin, 
trastuzumab), but this is an expensive option that not all patients can access and must still be 
frequently combined with chemotherapy drugs.2,3  
Protein nanoparticles (PNPs) are increasingly used in a wide variety of biotechnology 
settings due to their low toxicity, high potential specificity deriving from their polyvalent nature, 
and low cost. This project focuses on the modification of PNPs to target HER2-positive breast 
cancer cells for drug delivery.  The relative success of this project was determined by flow 
cytometry and fluorescence microscopy, which confirmed the binding of targeted PNPs and a 
lack of nonspecific binding. While further experimentation in cytotoxicity and in vivo studies is 
needed, this project presents a novel and successful method of targeting HER2-positive breast 
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Introduction 
Cancer treatment is an evolving field with many shortcomings. Amongst them is the 
balance between cancer destruction and patient health. Systemic cytotoxic drugs have been a 
common treatment since their discovery, but they are highly toxic to the patient and carry lifelong 
consequences. Prodrugs have been proposed as a solution to systemic therapy, but targeting is 
necessary for effective treatment. Protein nanoparticles (PNPs) can not only bind to tumors, but 
also stabilize the prodrug converting enzymes to preserve their activity. These particles are 
comprised of proteins that self-assemble into stable nanostructures, which can be chemically or 
genetically modified to target cells, deliver drugs, or induce apoptosis. Use of PNPs in these 
settings is increasing in the literature and showing effectiveness.4 These features qualify PNPs as 
potential immunotherapeutics against cancer, a disease characterized by unique cell surface 
receptors.  
Taking advantage of the versatility of protein engineering, PNPs can be designed to display 
antibody-binding domains, such as the Z-domain from S. aureus, enabling these PNPs to traffic to 
cancer cells by receptor-mediated targeting.5 This project focuses on the modification of protein 
nanoparticles for drug delivery via targeting against human epidermal growth factor receptor 2 
(HER2) positive breast cancer cells. Cancer cells are targeted by exterior modification of protein 
nanoparticles bearing Z domains, which bind anti-HER2 antibodies. These PNPs are engineered 
to package cytosine deaminase, a prodrug converting enzyme, which induces cell death by 
converting 5-flourocytosine, a systemically-administered prodrug, to 5-fluorouricil.  
Although diverse in pathophysiology and presentation, cancer is characterized by 
aberrant growth, avoidance of regulation, and overexpression of growth factors. Breast cancer 
frequently demonstrates mutated HER2; when mutated, HER2 allows uncontrolled cell division 
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that results in tumor formation. HER2-positive tumors occur in 15-20% of breast cancer and tend 
to be more aggressive and less sensitive to treatment than HER2-negative tumors.2 Herceptin, 
also known as trastuzumab, is an FDA approved therapy for HER2-positive metastatic breast 
cancer. This therapy consists of a monoclonal antibody that targets the HER2 receptor to block 
growth signals from reaching cells overexpressing HER2 and to promote immune response 
against bound cells.6 Frequently, Herceptin is coupled with chemotherapy to promote further cell 
cytotoxicity.2 However, it is well known that systemic drugs result in dangerous side effects to 
patients which is why this study proposes combining Herceptin with PNPs packaged with 
cysteine deaminase and 5-fluorocytosine, a chemotherapeutic prodrug. Herceptin will target 
PNPs to cancerous cells that are overexpressing HER2 while cysteine deaminase will convert 
systemically administered 5-fluorocytosine to toxic 5-fluorouracil to promote cytotoxicity of 
bound cells.  
Here, we test the ability of protein nanoparticles encapsidating prodrug-converting 
enzymes targeted by antibodies to HER2 positive breast cancer to improve targeted killing of 
tumors. PNPs were assembled from E. coli co-transformed with plasmids QB@CD and K46Q-
ZZ to synthesize coat protein and prodrug converting enzymes. PNPs were then modified with 
an anti-HER2 antibody and tagged with green fluorescent protein (GFP). The PNPs could then 
be analyzed for HER2 targeting ability via flow cytometry and microscopy on cell lines MDA-
MB-231, MDA-MB-435, HT-29, and HEK-293. MDA-MB-231, MDA-MB-435, and HT-29 
cells express HER2 while HEK-293 is a human embryonic kidney cell line incapable of HER2 
expression.8,9 
Both flow cytometry and microscopy were conducted on all four cell lines to show the 
ability of anti-HER2 antibody modified PNPs to target HER2-positive cells. Results for both 
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methods indicate that modified PNPs are effective at specifically targeting the HER2 receptor in 
vitro. Therefore, this method of modifying PNPs is promising as an effective, targeted drug 
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Materials and Methods 
Cloning and Protein Expression 
BL21 (DE3) competent E. coli cells were co-transformed with two plasmid DNAs (pCDF 
and pET) to allow for the production of the recombinant coat protein (CP) of the protein 
nanoparticle, Qß, and prodrug enzyme packaging. This was done by adding a DNA plasmid that 
contained the Qß CP and selective antibiotic resistance and a DNA plasmid that contained the 
prodrug enzymes and selective antibiotic resistance then heat shocking the cells. The cells were 
given an hour to recover then plated on a selective agar plate. After colonies have established, a 
colony was selected and allowed to inoculate in selective culture media. This culture grew in 
selective expression media until the correct optical density is measured. The expression culture 
was treated with ispropyl ß-D-1-thiogalactopyranoside (IPTG) and incubated overnight. The 
purpose of IPTG is to activate the lac operon in the cells and promote the expression of the Qß 
protein.10 
Particle Purification 
The Qß particles must then be purified from the cells. The expression cultures were 
centrifuged to isolate the cells. The pellets were resuspended in Tris buffered saline (TBS, pH: 
7.6) and sonicated to lyse the cells and release the Qß protein. The lysate was then centrifuged 
and the protein was precipitated with ammonium sulfate. This was repeated followed by an 
extraction with butanol: chloroform (1:1). A final centrifugation resulted in two liquid layers. 
The upper layer was transferred to a Falcon for further purification. Further purification was 
conducted using a 10:40 sucrose gradient. The gradients were then imaged using a light column 
on a fractionator stand after centrifugation for 4 hours. After the particles were extracted, they 
were then balanced with potassium phosphate buffer (pH: 7.4) and centrifuged for 2 more hours. 
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The pellet that resulted was then resuspended in potassium phosphate buffer and stored until 
characterization. 
Particle Characterization 
After purification, Qß particles needed to be characterized to ensure that the proteins are 
pure with the expected radii. Methods of characterization included dynamic light scattering 
(DLS), fast protein liquid chromatography (FPLC), and gel electrophoresis. DLS was performed 
with an ideal radius of 15 nm known from previous experimentation in the Finn lab. Ideally, the 
FPLC results would be consistent with the radius observed in DLS and with literature values for 
elution of Qß PNPs. FPLC is also a good measure of particle purity. The gel was run using a 
serial dilution with a protein standard. Once the run was complete, the gel was silver stained and 
showed the expected banding pattern for Qß indicating that the particles are ready for 
modification. 
Particle Modification 
Qβ(ZZ)@CD PNPs were labeled with anti-HER2 antibody. Briefly, PNPs were diluted to 
0.1 mg/mL and 20 µg PNP was incubated with 50 µg purified anti-human ErbB2/HER2 rat IgG2a 
(Clone ICR55, Thermo Fisher) for 2 h at 37°C. An antibody: ZZ-domain mole ratio of 0.75 was 
used for all labeling reactions and was sufficient for uniform labeling of the particles. To serve as 
a control, the same procedure was repeated with purified mouse IgG1, κ isotype control antibody 
(Clone MG1-45, BioLegend).  
Cell Culture  
 Four cell lines were cultured: HT-29, MDA-MB-435, MDA-MB-231 as HER2 positive 
lines and HEK-293 as a HER2 negative line. All lines were brought up from cryopreservation 
and were cultured in flasks using supplemented media. Flasks were split using Accutase every 2-
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4 days depending on the confluence of the adherent cells. When the PNPs were ready for 
application, cells were removed with Accutase from culture for either flow cytometry or 
microscopy. 
Flow Cytometry 
MDA-MB-435, MDA-MB-231, HT-29, and HEK-293 cells were grown to 90% 
confluence, detached with Accutase, pelleted, and re-suspended in FACS buffer. Approximately 
5 x 105 cells were aliquoted for each sample. PNPs were added directly to the cell suspensions at 
a final concentration of 10 nM and incubated at 4°C for 2 h. Cells were washed twice with FACS 
buffer and fixed with 2% paraformaldehyde for 15 min at room temperature. Following two 
additional washes, cells were re-suspended in FACS buffer and stored at 4°C until analysis. Cell 
populations, gated for live cells and 10,000 events, were collected using a BD LSRFortessa cell 
analyzer (BD Biosciences).  
Microscopy 
For fluorescence microscopy, cultured cells were imaged on an Eclipse Ti-U fluorescence 
microscope (Nikon). Prior to imaging, 5x105 cells (MDA-MB-435, MDA-MB-231, and HEK-
293) were seeded onto 8-chambered microscope slides and allowed to adhere overnight. The 
following day, cells were incubated for 2 hours at 4°C with 200 µL cell culture media containing 
anti-HER2 labeled antibody PNPs or unlabeled PNPs. Following incubation, cells were rinsed 
twice with 1x PBS and fixed with 2% paraformaldehyde for 15 min at room temperature. Cells 
were subsequently rinsed twice with 1x PBS and imaged immediately. Pictures were taken using 
NIS Elements imaging software (Nikon) and files were exported and analyzed using ImageJ 
software. 
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Results and Discussion 
Flow Cytometry 
 Flow cytometry data on all four cell lines provided promising preliminary data indicating 
PNPs may be capable of targeting cells which are overexpressing HER2. MDA-MB-435, MDA-
MB-231, HT-29, and HEK-293 cells were analyzed via flow cytometry with four experimental 
groups per cell line. Cells were treated with no particles, unlabeled PNPs, dummy labeled 
antibody PNPs, or anti-HER2 labeled PNPs. The no particle control group established the 
baseline reading of the cell line. The unlabeled PNPs control groups determined the “stickiness” 
of the particles or how much the particles adhere to cells without any type of targeting. The 
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is specific to the receptor. The anti-HER2 labeled PNPs group served as the experimental group 
for HER2 receptor targeting.  
 MDA-MB-435, MDA-MB-231, HT-29 are all HER2-positive cell lines although MDA-
MB-231 and HT-29 are only weakly positive. MDA-MB-435 cells showed a marked rightward 
shift in cell count in the experimental anti-HER2 labeled particle group from the control groups, 
which is promising for cell targeting potential (Figure 1a). The unlabeled particle and dummy 
antibody labeled particle groups showed only a slight shift from the background signal indicating 
a small amount of non-specific binding of particles. HT-29 cells also showed a rightward shift in 
cell count in the experimental anti-HER2 labeled particle group from the control groups, but the 
shift is smaller than the shift seen in the MDA-MB-435 cells (Figure 1b). Additionally, this cell 
type shows a higher amount of non-specific particle binding of unlabeled particles and dummy 
antibody labeled particles. HT-29 is only weakly HER2 positive so the smaller shift in 
experimental group is unsurprising. However, the amount of non-specific of binding should be 
monitored in future cytotoxicity assays. Non-specific binding could pose future problems when 
the prodrug converting enzymes convert prodrug to toxic bioactive drug. If there is a large 
amount of non-specific binding, healthy cells will be killed in addition to cancerous cells, which 
defeats the purpose of this engineered delivery system. MDA-MB-231 cells showed a large 
rightward shift in cell count in the experimental anti-HER2 labeled particle group from the 
background control group (Figure 1c). However, there is a large shift of the dummy antibody 
labeled particle group and unlabeled particle group indicating a large amount of non-specific 
binding, which again will need to be monitored in cytotoxicity assays. 
 HEK-293, a HER2 negative cell line used as a control, showed no rightward shift of the 
experimental group from the control groups (Figure 1d). This result indicates that particles are 
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not targeting any receptor other than HER2. Additionally, very little non-specific binding is 
observed in this cell type as indicated by the small rightward shift in unlabeled particle group and 
dummy antibody group. The results seen in HEK-293 provide further evidence that the shift seen 
in other cell lines in the experimental treatment group is due to HER2 targeting as opposed to 
other phenomena. Microscopy results should give further indication whether receptor targeting is 
occurring or not. 
Microscopy 
 MDA-MB-435 and HT-29 were analyzed by 
fluorescence microscopy. MDA-MB-231 and 
HEK-293 have yet to be analyzed due to a 
lack of viable cells in culture, but will be 
complete soon. Cells were treated with either 
unlabeled particles or anti-HER2 antibody 
labeled particles and imaged in both phase 
and fluorescence. Particles were made 
fluorescent by tagging them with GFP during 
antibody modification. Both MDA-MB-435 
and HT-29 showed no binding of particles when treated with unlabeled particles as indicated by 
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levels of non-specific binding, which agrees with the results seen for these cell lines in flow 
cytometry work (Figure 1). When 
treated with anti-HER2 labeled 
particles, both MDA-MB-435 and 
HT-29 show fluorescent binding of 
particles around the membranes of the 
cells (Figure 3). Since both of these 
cell lines are HER2 positive, this 
provides further evidence that HER2 
is being targeted on the cell 
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Conclusions and Future Experimentation 
 Flow cytometry and microscopy indicate that PNPs modified with anti-HER2 antibodies 
are capable of targeting cells that overexpress HER2. Several experiments are underway to 
confirm and establish the limits of this technology. First, fluorescence microscopy must be 
completed with all four cell types to confirm that the particles target all of the HER2-positive cell 
lines while leaving the HER2-negative cell line unaffected. Measurements of cellular viability 
(by MTT assay) will then be made, to establish if there is dose-dependent toxicity in vitro and to 
see this correlates with nonspecific or HER2-specific binding. If nonspecific PNP binding is 
found to induce cell death, the protein nanoparticle can be redesigned to minimize nonspecific 
association and explore the mechanism of such an effect. The negative cell line used here, HEK-
293, is a healthy human embryonic kidney cell line. It will also be useful to test a cancerous 
HER2-negative cell line to see if any different effects are observed. After establishing the 
parameters of cellular targeting, prodrug conversion will be engaged to establish the dose 
dependence of cytotoxicity by this mechanism in vitro. These studies will set the stage for testing 
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